Bioinformatics Genomics Research RNA 
pharmaphorum
JANUARY 19, 2022
Research into single-cell sequencing has been boosted with Single Cell Discoveries and BioTuring joining forces to refine the process. A rapidly growing field of research, single-cell RNA sequencing is vital for those working in areas such as oncology, immunology, and neuroscience.
Drug Discovery World
MARCH 4, 2024
Clinical Microbiomics has acquired DNASense, a Danish microbiome clinical research organisation (CRO) specialised in long-read DNA and RNA sequencing technologies and bioinformatics. The acquisition adds long-read DNA and RNA sequencing technologies to Clinical Microbiomics’ multi-omics technologies for the microbiome field.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Scienmag
OCTOBER 27, 2020
In the world of rare genetic diseases, exome and genome sequencing are two powerful tools used to make a diagnosis. A recent addition to the toolkit, RNA sequencing, has been demonstrated to help researchers narrow down disease candidate variants identified first on exome and genome sequencing.
Drug Discovery World
OCTOBER 26, 2023
While we are using standard commercially available processes for genomics, we have invested massively into high-throughput and high-resolution transcriptomics, proteomics, and metabolomics methods. The technologies cover the whole range of biomolecules from genes to protein to metabolites.
XTalks
DECEMBER 13, 2023
In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.
Drug Discovery World
APRIL 6, 2023
She is being recognised for her longstanding commitment as a patient advocate for American Indian Tribes across the Mountain West and beyond, and for her commitment to improving health literacy and clinical trial enrolment among American Indian populations.
Drug Discovery World
JULY 11, 2023
Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.
Expert insights. Personalized for you.
71 
Let's personalize your content